Recent data from Anavex Life Sciences has brought hopeful news in the fight against Alzheimer’s disease. In a
Phase 2b/3 trial, Anavex Life Sciences’ investigational drug, blarcamesine,
demonstrated a significant reduction in pathological amyloid-ß levels, a key
biomarker associated with the progression of Alzheimer’s.
The trial, conducted by Anavex Life Sciences, enrolled 508 participants with early symptomatic
Alzheimer’s disease. Participants were randomized to receive either
blarcamesine or a placebo for 48 weeks. The primary endpoints of the study were
the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and the
Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
subscales, both of which are standard measures of cognitive and functional efficacy.
Results showed that participants treated with blarcamesine had a significant slowing in the rate of
brain atrophy, as observed through MRI scans. Additionally, the plasma Aβ42/40
ratio, another critical biomarker, showed notable improvement.
“This trial underscores the potential of blarcamesine to make a meaningful impact on
neurodegeneration associated with Alzheimer’s disease,” said Marwan Noel
Sabbagh, MD, professor of neurology and chairman of the Scientific Advisory Board.
The study also reported that the most common treatment-emergent adverse event was dizziness,
which was generally mild to moderate in severity.
Christopher U Missling, PhD, president and CEO of Anavex, expressed gratitude to all involved
in the study. “Anavex is committed to advancing blarcamesine as a potential new
treatment option for Alzheimer’s disease,” he stated.
As the fight against Alzheimer’s continues, the findings from Anavex offer a glimmer of hope for those affected by this debilitating
condition. The advancements made through this trial highlight the potential for
new, more effective treatments on the horizon.
See related link for additional information.
Learn more about Anavex on https://www.nasdaq.com/market-activity/stocks/avxl